Trial Profile
An Open Label, Phase I Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Linagliptin (BI 1356) 5 mg After Single and Multiple Oral Administration in Patients With Type 2 Diabetes Mellitus of African American Origin for 7 Days.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 14 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 14 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2010 Planned end date changed from 1 Jul 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.